Showing results (51-60 of 282) with videos related to
Sort By:
Pageof 29
Blood|August 27, 2011
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centersKiran Naqvi, Elias Jabbour, Carlos Bueso-Ramos, et al.Clinical Lymphoma, Myeloma & Leukemia|May 18, 2011
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implicationsAli Al Ameri, Elias Jabbour, Guillermo Garcia-Manero, et al.Cancer|May 15, 2009
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemiaGautam Borthakur, E Lin, Nitin Jain, et al.Plos One|April 3, 2014
Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrestIrene Gañán-Gómez, Yue Wei, Hui Yang, et al.Cancer|June 24, 2005
Outcome of patients with acute myelogenous leukemia after second salvage therapyFrancis Giles, Susan O'Brien, Jorge Cortes, et al.Blood|August 4, 2007
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemiaEhab Atallah, Jorge Cortes, Susan O'Brien, et al.Leukemia Research|July 23, 2014
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemiaNaval Daver, Aditi Shastri, Tapan Kadia, et al.Cancer|July 23, 2020
Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib eraLucia Masarova, Prithviraj Bose, Naveen Pemmaraju, et al.Cancer|August 26, 2010
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission durationHagop M Kantarjian, Deborah Thomas, Farhad Ravandi, et al.Cancer|June 22, 2010
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunctionWei-Gang Tong, Hagop Kantarjian, Susan O'Brien, et al.Pageof 29